You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In an opinion piece at the Guardian, Adam Rutherford consumer genetic testing customers realize they are the product.
A number of consumer genetic testing companies are adopting best practice guidelines for customer privacy, the Washington Post reports.
With a $300 million investment in 23andMe, GSK pivots toward personalized medicine again, while the consumer genomics firm hitches its drug development ambitions to GSK.
Pharmaceutical company GlaxoSmithKline and direct-to-consumer genetic testing company 23andMe have formed a drug discovery collaboration deal.
The companies will initially contribute equally to funding the collaboration and will share in future proceeds from drugs developed within the partnership.
The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.
Researchers sequenced mothers who experienced preterm birth and found a possible role for steroid signaling in birth timing.
Third-party analyses of raw data from direct-to-consumer genetic testing companies may not always be right, the New York Times reports.
Immigrant aid group turns down direct-to-consumer genetic testing company 23andMe's offer to help reunite separated families, according to KQED.
Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.
A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.
Nature News writes that viral genomic surveillance in the US faces systemic issues.
President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.
In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.